UOC
RVNC

UBS O'Connor’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS O'Connor’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-325,314
Closed -$836K – 629
2024
Q2 		$836K Buy
325,314
+70,647
+28% +$241K 0.02% 318
2024
Q1 		$1.25M Buy
254,667
+145,000
+132% +$858K 0.04% 252
2023
Q4 		$964K Buy
109,667
+20,867
+23% +$171K 0.03% 275
2023
Q3 		$1.02M Buy
+88,800
New +$1.71M 0.02% 329
2023
Q2 		– Sell
-20,214
Closed -$651K – 655
2023
Q1 		$651K Buy
+20,214
New +$630K 0.02% 445
2022
Q4 		– Sell
-101,179
Closed -$2.73M – 386
2022
Q3 		$2.73M Sell
101,179
-74,000
-42% -$1.5M 0.03% 466
2022
Q2 		$2.42M Buy
+175,179
New +$2.7M 0.03% 613

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

UBS O'Connor's RVNC Position: Q3 2024 in Review

UBS O'Connor sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 325,314 shares — an estimated $836K sold.

UBS O'Connor first reported a position in RVNC in Q2 2022 and held it in 7 quarters. The position peaked at $2.73M in Q3 2022. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • UBS O'Connor reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • UBS O'Connor sold 325,314 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $836K.
  • UBS O'Connor first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 7 quarters.
  • UBS O'Connor's Revance Therapeutics, Inc. position peaked at $2.73M in Q3 2022.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.